Ann: SPL7013 shows potent antiviral activity in RSV, page-61

I don't go in for the name calling @thrasher....not defending col@69. His point like many here has the same theme. That is when do we commercialise all the science?just because some pharma unknown wants additional testing on dep drug plus drug, doesn't mean our $ are spent on that research.
The nasal spray may have many options so what, get it launched. What's the hold up?
$48m in bamk after CR, has to be for commercialisation not lab tests.
Are we a research company or a seller of products?
Revenue and SH returns is long overdue.